| Original language | English (US) |
|---|---|
| Pages (from-to) | 2106-2109 |
| Number of pages | 4 |
| Journal | Blood |
| Volume | 135 |
| Issue number | 23 |
| DOIs | |
| State | Published - Jun 4 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. / Neelapu, Sattva S.; Jacobson, Caron A.; Oluwole, Olalekan O. et al.
In: Blood, Vol. 135, No. 23, 04.06.2020, p. 2106-2109.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
AU - Neelapu, Sattva S.
AU - Jacobson, Caron A.
AU - Oluwole, Olalekan O.
AU - Munoz, Javier
AU - Deol, Abhinav
AU - Miklos, David B.
AU - Bartlett, Nancy L.
AU - Braunschweig, Ira
AU - Jiang, Yizhou
AU - Kim, Jenny J.
AU - Zheng, Lianqing
AU - Rossi, John M.
AU - Locke, Frederick L.
N1 - Funding Information: This work was supported by Kite, a Gilead Company, and the Leukemia and Lymphoma Society Therapy Acceleration Program. Medical writing support was provided by Jennifer Leslie, of Nexus Global Group Science, with funding from Kite. Funding Information: Conflict-of-interest disclosure: S.S.N. has received personal fees from Kite, Merck, Novartis, Celgene, Pfizer, Allogene, Cell Medica, Incyte, Precision Biosciences, Legend Biotech, and Unum Therapeutics and research support from Kite, Bristol-Myers Squibb, Merck, Poseida, Cel-lectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene, and Acerta. C.A.J. has received personal fees from Kite, Novartis, Precision Bioscience, Bayer, Pfizer, and Humanigen. J.M. has served in a consultancy or advisory role for Genentech, Alexion, Bayer, Bristol-Myers Squibb, Juno/Celgene, Kite, Kyowa, Merck, Pfizer, Pharmacyclics/ Janssen, and Seattle Genetics; has served on speakers’ bureaus for AstraZeneca, Bayer, Fosunkite, Genentech, Kite, Kyowa, Pharmacyclics/ Janssen, and Seattle Genetics; and has received research funding from Celgene, Genentech, Incyte, Janssen, Kite, Pharmacyclics, Portola, and Seattle Genetics. A.D. has served on advisory boards for Kite, Agios, and Novartis and has received research funding from Bristol-Myers Squibb. D.B.M has received grants and research funding from and served on a scientific advisory board for Kite. N.L.B has received research funding from Affimed, Bristol-Myers Squibb, Celgene, Forty Seven, Genentech, Gilead, Immune Design, Kite, Merck, Millennium, and Pharmacyclics and serves on advisory boards for Acerta and ADC Therapeutics. I.B. has received speaker fees from Kite. Y.J., J.J.K., L.Z., and J.M.R. are employees of Kite and have equity ownership in Gilead Sciences Inc. F.L.L has been a scientific advisor to Kite, Novartis, and GammaDelta Therapeutics and is a consultant for Cellular Biomedicine Group Inc. The remaining authors declare no competing financial interests.
PY - 2020/6/4
Y1 - 2020/6/4
UR - http://www.scopus.com/inward/record.url?scp=85085664138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085664138&partnerID=8YFLogxK
U2 - 10.1182/BLOOD.2019004162
DO - 10.1182/BLOOD.2019004162
M3 - Letter
C2 - 32181801
AN - SCOPUS:85085664138
VL - 135
SP - 2106
EP - 2109
JO - Blood
JF - Blood
SN - 0006-4971
IS - 23
ER -